NTRC, a biopharmaceutical company focused on the discovery and development of innovative precision medicines for the treatment of cancer, today announced that the United States Patent and Trademarks Office (USPTO) has granted patent protection for a key patent for its TTK kinase inhibitor programme.

The spindle assembly checkpoint TTK, also known as Mps1, is a key regulator of chromosome segregation and a promising new drug target for the treatment of cancer. Scientists at NTRC, based in Oss, The Netherlands, designed and optimized the novel TTK inhibitors, which exhibit high biochemical and cellular potency. The TTK inhibitors are based on a (5,6-dihydro)pyrimido[4,5-e]indolizine scaffold. This is a completely novel class of synthetic chemical molecules, which are described for the first time in the NTRC patent (WO 2015/155042 A1). The NTRC TTK inhibitors demonstrate very potent anti-proliferative activity in cell-based assays, in the same range as classic cytotoxic agents, but show preference for tumour cells with activated Wnt signalling. In several in vivo cancer models, lead compounds from the series have shown strong reduction of tumour growth or even tumour regression, without toxicity.

For more information visit the NTRC website.